Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Stefan Sziegoleit"'
1
Akademický článek
DIVE/DPV registries: benefits and risks of analog insulin use in individuals 75 years and older with type 2 diabetes mellitus
Autor: Peter Bramlage, Sascha R Tittel, Gesine van Mark, Reinhard Welp, Jörg Gloyer, Stefan Sziegoleit, Ralf Barion, Peter M Jehle, Dieter Erath, Stefanie Lanzinger
Publikováno v: BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
Introduction The aims of this study were to characterize insulin-treated individuals aged ≥75 years with type 2 diabetes using basal insulin analogs (BIA) or regular insulins (human insulin (HI)/neutral protamine Hagedorn (NPH)) and to compare the
Externí odkaz: https://doaj.org/article/ada6db58000c4f9985f7167a9ea4fe8a
Zobrazit plný text záznamu
2
Akademický článek
Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases
Autor: Gesine van Mark, Sascha R. Tittel, Stefan Sziegoleit, Franz Josef Putz, Mesut Durmaz, Michaela Bortscheller, Ivo Buschmann, Jochen Seufert, Reinhard W. Holl, Peter Bramlage
Publikováno v: Therapeutic Advances in Endocrinology and Metabolism, Vol 11 (2020)
Background: The clinical profile differs between old and young patients with type 2 diabetes mellitus (T2DM). We explored, based on a large real-world database, patient and disease characteristics and actual treatment patterns by age. Methods: The an
Externí odkaz: https://doaj.org/article/6a9554b72f074f9c942921076b16a82d
Zobrazit plný text záznamu
4
Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries
Autor: Reinhard W. Holl, Maike Plaumann, Stefan Sziegoleit, Gesine van Mark, Peter Bramlage, Dpv, Bettina Hartmann, Mesut Durmaz, Stefanie Lanzinger, Frank Jürgen Wosch, Dive registry initiatives, Jochen Seufert
Publikováno v: Acta Diabetologica. 57:229-236
Our study aimed to analyse treatment strategies after failure of initial metformin mono-therapy in adult patients with type-2 diabetes (T2DM). The DIVE and DPV databases were combined and 16,681 adult patients with T2DM and metformin mono-therapy ide
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab99128af0b64d801c00a733f2724e5d
https://doi.org/10.1007/s00592-019-01409-3
Zobrazit plný text záznamu
5
Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries
Autor: Franz Josef Putz, Stefan Sziegoleit, Reinhard W. Holl, Peter Bramlage, Mesut Durmaz, Stefanie Lanzinger, Jochen Seufert, Thomas Danne, Michaela Borscheller, Gesine van Mark
Publikováno v: Advances in Therapy. 36:1628-1641
Insulin glargine 300 U/ml (U300) was registered based on the EDITION clinical trial program. The aim of this database analysis was to describe the profile of adult U300 recipients with type-1 (T1DM) or type-2 diabetes (T2DM). The analysis was based o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::499060723dab8b6c10b50dd6c50af991
https://doi.org/10.1007/s12325-019-00983-w
Zobrazit plný text záznamu
6
DIVE/DPV registries: benefits and risks of analog insulin use in individuals 75 years and older with type 2 diabetes mellitus
Autor: Stefanie Lanzinger, Reinhard Welp, Sascha R. Tittel, Dieter Erath, Gesine van Mark, Jörg Gloyer, Peter Bramlage, Stefan Sziegoleit, Peter M. Jehle, Ralf Barion
Publikováno v: BMJ Open Diabetes Research & Care
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
IntroductionThe aims of this study were to characterize insulin-treated individuals aged ≥75 years with type 2 diabetes using basal insulin analogs (BIA) or regular insulins (human insulin (HI)/neutral protamine Hagedorn (NPH)) and to compare the b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31252b4bf6e1b534e49f3099f05b1c51
https://pubmed.ncbi.nlm.nih.gov/34083247
Zobrazit plný text záznamu
7
Type 2 diabetes in older patients: an analysis of the DPV and DIVE databases
Autor: Reinhard W. Holl, Michaela Bortscheller, Sascha R. Tittel, Franz Josef Putz, Peter Bramlage, Stefan Sziegoleit, Jochen Seufert, Mesut Durmaz, Ivo Buschmann, Gesine van Mark
Publikováno v: Therapeutic Advances in Endocrinology and Metabolism
Therapeutic Advances in Endocrinology and Metabolism, Vol 11 (2020)
The clinical profile differs between old and young patients with type 2 diabetes mellitus (T2DM). We explored, based on a large real-world database, patient and disease characteristics and actual treatment patterns by age.
publishedVersion
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76be31a20c7f60d9dbba116e2b069447
Zobrazit plný text záznamu
8
Welche Patienten aus der Routinebetreuung verwenden das neue Insulin-Analogon Glargin U300 im Vergleich zu Patienten mit Glargin U100?
Autor: Michael Hummel, Artur Zimmermann, Reinhard W. Holl, Barbara Bohn, Hans Martin Reuter, Jörg Gloyer, Thomas Danne, Reinhard Welp, Stefan Sziegoleit, Peter Bramlage, Christian Wagner, Matthias Kaltheuner
Publikováno v: Wiener Medizinische Wochenschrift. 168:415-422
Glargin U300 (Gla-300) ist eine Weiterentwicklung von Glargin U100 (Gla-100) und seit 2015 in Deutschland und Osterreich erhaltlich. Ziel war es zu untersuchen, wie sich auf Gla-300 ein-/umgestellte Patienten von zeitgleich auf Gla-100 eingestellte P
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::28e7b54723717998e85b59f25c39075e
https://doi.org/10.1007/s10354-017-0589-8
Zobrazit plný text záznamu
9
[Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE]
Autor: Barbara, Bohn, Peter, Bramlage, Christian, Wagner, Matthias, Kaltheuner, Reinhard, Welp, Stefan, Sziegoleit, Artur, Zimmermann, Hans Martin, Reuter, Michael, Hummel, Jörg, Gloyer, Reinhard W, Holl, Thomas, Danne
Publikováno v: Wiener medizinische Wochenschrift (1946). 168(15-16)
Glargine U300 (Gla-300) is a further development of glargine U100 (Gla-100). Since 2015, Gla-300 has been available in Germany and Austria. We compared patients initiating therapy with Gla-300 with patients starting with Gla-100. Moreover, it was inv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::651cc5d9c9f0ad1b90c0f4638880ccca
https://pubmed.ncbi.nlm.nih.gov/28828553
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje